Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

  • Br J Haematol. 2018 Sep;182(6):927-930. doi: 10.1111/bjh.14884.
Abraham M Varghese  1 ,  Andy Rawstron  2 ,  Darren Newton  3 ,  Reuben M Tooze  3 ,  Talha Munir  1 ,  Marion Dickson  4 ,  Gina M Doody  3 ,  Peter Hillmen  1
Affiliations
  • 1. Department of Haematology, St. James's University Hospital, Leeds, UK.
  • 2. Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
  • 3. Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • 4. Immunoinflammation Therapy Area, GlaxoSmithKline, Stevenage, UK.
PMID: 28770560 DOI: 10.1111/bjh.14884
Products